Nanobiotix S.A. announced that the first patient has been injected in a Phase 1/2 study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1/L-1 immune checkpoint inhibitors for the treatment of patients with advanced solid tumor malignancies that have spread to lungs (lung metastases) and/or liver (liver metastases). The trial (NCT05039632) is being conducted as part of an ongoing strategic collaboration between Nanobiotix and The University of Texas MD Anderson Cancer Center evaluating radiotherapy-activated NBTXR3 across solid tumor indications and treatment combinations. This new study expands the ongoing strategic collaboration to five actively recruiting trials.

Beyond the new study, the additional active studies in the collaboration include: A Phase 2 study of radiotherapy-activated NBTXR3 in combination with anti-PD-1 for patients with recurrent or metastatic head and neck cancer (NCT04862455); A Phase 1 study of radiotherapy-activated NBTXR3 for patients with inoperable non-small cell lung cancer (NCT04505267); A Phase 1 study of radiotherapy-activated NBTXR3 for patients with pancreatic cancer (NCT04484909); A Phase 1 study of NBTXR3 activated by radiotherapy in combination with chemotherapy for patients with esophageal cancer (NCT04615013).